Ann: PAR Reports Phase 3 Clinical Trial Update, page-27

Goldmad, Most welcome....Questions and comments from you and so many others helps us all....


New guys to us, do not be hesitant to ask questions...even if they have been asked before, ask them...A number of ace posters here, much more knowledgeable than me, endeavour to have the patience to answer them even if answered a few times before. It can result us in researching more and discussing it more thoroughly.


Something triggered by your astute comments/questions was indeed niggling at me saying there is some small article that I've come across in the distant past in regards to the 3 mg/kg weekly dosing regime....I found it!

--------------------






It was in this study some 114 patients (54 active and 60 control) were taken and were dosed with 3mg/kg once a week for just 4 weeks in Perth, Australia.

In three distinct clinical assessments there were significant differences between the groups that were observed.

1. duration of joint stiffness p < 0.015
2. pain at rest P ≤ 0.017
3. patient global assessment P <- 0.006

Getting such good p values in just n = 114 speaks for itself.


The rates of trial continuation were higher in the active group.


In the Active Daily Living categories..."...functional improvement from baseline was found at weeks 8 and 12 in the NaPPS group".





The final conclusion was stated as follows:





"In this pilot study, 4 weekly injections of NaPPS were associated with significantly improved duration of joint stiffness and pain at rest compared with controls for 20 weeks after the cessation of treatment, and significantly improved pain on walking and overall function for 8 weeks after the cessation of treatment in these patients with OA of the knee".




However what interested me more than the conclusion was this one paragraph, DMOAD connotations....the real gold, take a read of this one:






Because NaPPS is not an analgesic and is cleared from the plasma within 12 hours and from body tissues within a few weeks of administration, we can suggest that the symptom relief reported by patients for up to 20 weeks after the end of administration might have been related to NaPPS modification of some aspects of OA pathobiology associated with clinical symptoms. This suggestion is consistent with those from laboratory and animal model studies that found that NaPPS was associated with reduced joint inflammation, improved blood flow in subchondral bone and soft tissues, and preserved proteoglycan and hyaluronan concentrations in articular cartilage and synovial fluid.





iPPS is cleared from plasma in 12 hours and within a few weeks in tissues.





Paradigmers, the above results were based off ONLY 4 weeks, 3mg/kg.



I give you the amazing power of iPPS.







- Mozz







ps: DYOR



Reference:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965979/